Medical devices, healthcare technology and the business of care
COMPANY INTELLIGENCE

Mobia Medical, Inc.

Explore this company’s associated devices, FDA decisions and regulatory history.

Clinical monitoring equipment, editorial photography

Mobia Medical, Inc.

Regulatory records
9
Linked recall entries
0
Headquarters
Not reported
Brand website
Not reported
COMPANY INTELLIGENCE

What the linked records show

MedtechLedger currently links 9 FDA records to the applicant name Mobia Medical, Inc.. It includes 1 original PMA approval. 1 entry is a PMA supplement. 7 entries are 30-day notices. These are records held by this publication, rather than a count of the company’s entire portfolio.

The dated entries run from Aug 27, 2021 to Sep 16, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.

Product code QPY appears in 9 of the 9 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.

The largest PMA family in this collection is P210007, with 9 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 1 linked filing has a current plain-language explanation checked against the recorded FDA decision.

Applicant mailing address recorded by FDA: 2802 Flintrock Trace, Suite 226, Austin, TX, 78738. Recorded on P210007/S015, decision dated Sep 16, 2026.

Changes described in PMA records

P210007/S015: Vivistim System

The FDA recorded decision OK30 on 2026-09-16 for P210007/S015, a 30-Day Notice supplement to the Vivistim® System held by Mobia Medical, Inc. The supplement reason is listed as a process change involving manufacturer, sterilizer, packager or supplier. The device category is an implanted autonomic nerve stimulator for stroke rehabilitation, with product code QPY and Physical Medicine as the specialty.

The recorded change concerns one component: Mobia Medical replaced the supplier of the Lead Connector Boot used in the Implantable Lead of the Vivistim Paired VNS System, moving from Trelleborg to ProMed. This notice covers that supplier substitution, not a new approval of the full system. The source does not include supporting documents, review detail, or any clinical or performance findings, so the basis for OK30 and any effect on the finished lead remain unknown.

FDA approval-order wording

Mobia Medical has replaced their supplier for the Lead Connector Boot component of the Implantable Lead of the Vivistim Paired VNS System, transitioning from Trelleborg to ProMed.

Sep 16, 2026 · 30-Day Notice

P210007/S012: Vivistim Paired VNS System

FDA’s recorded scope: approval to implement two manufacturing changes pertaining to the Lead and Can Lids of the Vivistim Paired VNS System

Apr 1, 2026 · 30-Day Notice

Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.

Regulatory record history

Product / regulatory recordCompanyPathwayDecision dateSource
Vivistim SystemP210007/S015
Mobia Medical, Inc.PMA supplementSep 16, 2026FDA
Mobia Medical, Inc.PMA supplementJun 18, 2026FDA
Vivistim SystemP210007/S013
Mobia Medical, Inc.PMA supplementApr 10, 2026FDA
Mobia Medical, Inc.PMA supplementApr 1, 2026FDA
Vivistim SystemP210007/S011
Mobia Medical, Inc.PMA supplementMar 2, 2026FDA
Mobia Medical, Inc.PMA supplementFeb 26, 2026FDA
Vivistim SystemP210007/S010
Mobia Medical, Inc.PMA supplementJan 28, 2026FDA
Vivistim SystemP210007/S007
Mobia Medical, Inc.PMA supplementSep 3, 2025FDA
Mobia Medical, Inc.PMA approvalAug 27, 2021FDA
Source information

Source updated Nov 9, 2026. Retrieved Nov 21, 2026.